Louis Lacombe
Chercheur universitaire clinicien
Axe Oncologie
Métastases et progression du cancer
Mécanismes de la carcinogenèse
Urologie
Oncologie clinique
Dernières nouvelles
Centre de recherche
Le Centre de recherche du CHU de Québec sur le point de doubler son volume d’études cliniques précoces
Centre de recherche
Quand l’ARN tourne en rond
Centre de recherche
Un groupe de 7 chercheurs du CRCHU de Québec publie dans Nature une importante étude sur le cancer de la prostate
Publications
Voir tout-
article Wissing M, Brimo F, McKercher G, Scarlata E, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, Chevalier S, Aprikian A
Long term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada
Hum Pathol 146 2024.
-
article Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Perini RF, Sharma M, Peng X, Lee CH
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Lancet Oncol 24 (8), 2023.
-
article Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP and Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
J Immunother Cancer 10 (8), 2022.
Projets
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, du 2021-10-01 au 2026-09-30
- UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, du 2023-09-01 au 2025-08-31
- A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma, du 2023-09-22 au 2028-12-25
- Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial , du 2024-06-17 au 2025-06-16
- Metabolomics and lipidomics of prostate cancer progression: Leveraging the PROCURE Biobank, du 2024-07-10 au 2025-03-31
- Soutien à la recherche, du 2017-07-01 au 2024-06-30
- Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression, du 2021-09-01 au 2023-08-31